Esperion Therapeutics, Inc.(ESPR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

Esperion Therapeutics, Inc. (ESPR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ESPR at 46.3/100 on a 32-signal composite quality model, placing it at rank #1,835 of 2,962 stocks — the bottom half of the AI-ranked universe. ESPR scores in the top quartile across institutional flow (92.5), revenue growth (89.6). Areas of concern include earnings quality (1.3) and free cash flow (20.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Esperion Therapeutics, Inc. reports quarterly revenue of $80.1M, net income of $-25.2M, free cash flow of $-27.9M. Top institutional holders of ESPR by reported 13-F value include BlackRock, WASATCH ADVISORS, Two Seas Capital, based on the most recent SEC filings. ESPR trades on the Nasdaq exchange and files with the SEC under CIK 1434868. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ESPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Esperion Therapeutics, Inc. directly from SEC EDGAR.